Sensus Healthcare, Inc. (NASDAQ:SRTS) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Sensus Healthcare, Inc. (NASDAQ:SRTS) have received an average rating of “Moderate Buy” from the seven brokerages that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $6.8750.

SRTS has been the subject of a number of analyst reports. Weiss Ratings reissued a “sell (d)” rating on shares of Sensus Healthcare in a research report on Tuesday, April 21st. Wall Street Zen lowered shares of Sensus Healthcare from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 9th. Finally, Citigroup reaffirmed a “buy” rating on shares of Sensus Healthcare in a report on Friday, May 8th.

Sensus Healthcare Trading Down 1.4%

Shares of SRTS stock opened at $2.92 on Friday. The company’s fifty day simple moving average is $3.12 and its 200-day simple moving average is $3.91. The company has a market cap of $48.06 million, a PE ratio of -6.21 and a beta of 1.09. Sensus Healthcare has a 52 week low of $2.66 and a 52 week high of $5.92.

Sensus Healthcare (NASDAQ:SRTS) last issued its earnings results on Thursday, May 7th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.04). The company had revenue of $3.39 million during the quarter, compared to analysts’ expectations of $5.32 million. Sensus Healthcare had a negative return on equity of 15.79% and a negative net margin of 34.50%.

Institutional Investors Weigh In On Sensus Healthcare

Institutional investors have recently modified their holdings of the stock. State Street Corp grew its stake in Sensus Healthcare by 5.2% in the fourth quarter. State Street Corp now owns 69,252 shares of the company’s stock worth $276,000 after purchasing an additional 3,400 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Sensus Healthcare by 2.5% during the 2nd quarter. Geode Capital Management LLC now owns 153,917 shares of the company’s stock worth $730,000 after buying an additional 3,766 shares during the last quarter. Sachetta LLC lifted its holdings in Sensus Healthcare by 6.8% during the 4th quarter. Sachetta LLC now owns 148,508 shares of the company’s stock worth $591,000 after buying an additional 9,500 shares during the last quarter. Mindset Wealth Management LLC grew its position in shares of Sensus Healthcare by 28.1% in the 3rd quarter. Mindset Wealth Management LLC now owns 50,100 shares of the company’s stock worth $157,000 after acquiring an additional 11,000 shares in the last quarter. Finally, Opes Wealth Management LLC bought a new stake in shares of Sensus Healthcare in the 3rd quarter valued at approximately $50,000. Institutional investors and hedge funds own 25.30% of the company’s stock.

About Sensus Healthcare

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.